You are viewing the site in preview mode
Skip to main content
| |
Pediatric HSCT recipients (n = 16)
|
|---|
|
Transplant-related characteristics
|
|
Age at time of HSCT, years
|
7.2 ± 5.3
|
|
Time after HSCT, years
|
14.8 ± 5.0
|
|
Malignant disorder, n (%)
|
10 (62.5%)
|
|
ALL or AML
|
8
|
|
MDS or CML
|
2
|
|
Non-malignant disorder, n (%)
|
6 (37.5%)
|
|
Hematological disease
|
4
|
|
Other
|
2
|
|
Anthracycline therapy, n (%)
|
7 (43.8%)
|
|
< 300 mg/m2
|
5
|
|
≥ 300 mg/m2
|
2
|
|
Radiotherapy, n (%)
|
8 (50.0%)
|
|
Total body irradiation
|
7
|
|
Chest irradiation
|
1
|
|
Cyclophosphamide therapy, n (%)
|
14 (87.6%)
|
|
< 1 g/m2
|
1
|
|
≥ 1 g/m2
|
13
|
|
Allogeneic HSCT, n (%)
|
15 (94%)
|
|
HLA-identical sibling
|
6
|
|
Other related or unrelated donor
|
9
|
|
Graft versus host disease, n (%)
|
5 (31.3%)
|
|
Acute
|
2
|
|
Chronic
|
3
|
|
Clinical parameters
|
|
Systolic blood pressure, mmHg
|
121 ± 12
|
|
Diastolic blood pressure, mmHg
|
76 ± 9
|
|
Pulse, beats per minute
|
75 ± 12
|
- Values are presented as numbers (percentages) or means ± standard deviations. HSCT hematopoietic stem cell transplantation, ALL acute lymphatic leukemia, AML acute myeloid leukemia, MDS myelodysplastic syndrome, CML chronic myeloid leukemia
